Quarterly Conference Calls, In Brief
Executive Summary
Bristol earnings restatement: Bristol-Myers Squibb expects to "reallocate" approximately $2 bil. in sales recorded during 2000 and 2001 in its upcoming 10-Q filing with the Securities & Exchange Commission. "The expected restatement is based on further review and consideration of the company's accounting for its previously disclosed wholesaler inventory situation and on recent advice from the company's auditors, PricewaterhouseCoopers LLP, based on their ongoing assessment of the company's sales practices in the U.S. pharmaceuticals business and related accounting," Bristol says. The company's accounting for wholesaler inventories is under investigation by the SEC and Department of Justice (1"The Pink Sheet" Oct. 14, In Brief)....One way to boost earnings: Bristol earnings restatement will result in increases in reported revenues and earnings in 2002 (and decreases in 2000 and 2001)...
You may also be interested in...
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering-Plough prescription Claritin availability will not overlap with OTC loratadine once the switched drug becomes available in December
Schering OTC Claritin Will Launch In December Without Rx Transition Period
Schering-Plough prescription Claritin availability will not overlap with OTC loratadine once the switched drug becomes available in December
DoJ joins SEC in looking at Bristol
The U.S. Attorney's Office in New Jersey "has started looking into the company's wholesaler inventory situation," Bristol reports. SEC has already opened a formal inquiry into the company's handling of inventory levels, which led Bristol to sharply cut its earnings forecasts for this year. The New Jersey investigation follows a recent meeting between SEC staff and healthcare fraud prosecutors to discuss industry accounting practices (1"The Pink Sheet" Sept. 23, p. 23)...